Hostname: page-component-758b78586c-cmtlc Total loading time: 0 Render date: 2023-11-29T03:32:12.914Z Has data issue: false Feature Flags: { "corePageComponentGetUserInfoFromSharedSession": true, "coreDisableEcommerce": false, "useRatesEcommerce": true } hasContentIssue false

Secular Trends of Hospitalization With Vancomycin-Resistant Enterococcus Infection in the United States, 2000–2006

Published online by Cambridge University Press:  02 January 2015

Andrew M. Ramsey
School of Public Health and Health Sciences, University of Massachusetts, Amherst
Marya D. Zilberberg*
School of Public Health and Health Sciences, University of Massachusetts, Amherst EviMedResearch Group, Goshen, Massachusetts
EviMedResearch Group, PO Box 303, Goshen, MA 01032 (


Although the incidence of hospitalizations with infection due to vancomycin-resistant pathogens in the United States remained stable during 2000–2003, it increased from 4.60 to 9.48 hospitalizations per 100,000 population during 2003–2006. Hospitalizations with infection due to vancomycin-resistant pathogens also increased as a proportion of all US hospitalizations, from 3.16 to 6.51 hospitalizations with VRE infection per 10,000 total hospitalizations during 2003–2006. The number of hospitalizations with infection due to vancomycin-resistant pathogens is increasing in the United States. Because infection due to vancomycin-resistant organisms is associated with poor outcomes, the epidemiology of this trend needs further exploration.

Concise Communications
Copyright © The Society for Healthcare Epidemiology of America 2009

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)


1.Safdar, N, Maki, DG. The commonality of risk factors for nosocomial colonization and infection with antimicrobial-resistant Staphylococcus aureus, enterococcus, gram-negative bacilli, Clostridium difficile, and Candida. Ann Intern Med 2002;136:834844.Google Scholar
2.Kuehnert, MJ, Hill, HA, Kupronis, BA, Tokars, JI, Solomon, SL, Jernigan, DB. Methicillin-resistant Staphylococcus aureus hospitalizations, United States. Emerg Infect Dis 2005;11:868872.Google Scholar
3.McDonald, LC, Owings, M, Jernigan, DB. Clostridium difficile infection in patients discharged from US short-stay hospitals, 1996–2003. Emerglnfect Dis 2006;12:409415.Google Scholar
4.Zilberberg, MD, Shorr, AF, Kollef, MH. Secular trends in candidemia hospitalizations in the US, 2000–2005. Infect Control Hosp Epidemiol 2008;29:978980.Google Scholar
5.Zilberberg, MD, Shorr, AF, Kollef, MH. Increase in adult Clostridium difficile-related hospitalizations and case-fatality rate, United States, 2000-2005. Emerg Infect Dis 2008;14:929931.Google Scholar
6.Rafferty, ME, McCormick, MI, Bopp, LH, et al.Vancomycin-resistant enterococci in stool specimens submitted for Clostridium difficile cyto-toxin assay. Infect Control Hosp Epidemiol 1997;18:342344.Google Scholar
7.HCUPnet. Healthcare Cost and Utilization Project (HCUP). 2000-2004. Agency for Healthcare Research and Quality, Rockville, MD. Available at: Accessed May 24, 2008.Google Scholar
8.Sievert, DM, Rudrik, JT, Patel, JB, et al.Vancomycin-resistant Staphylococcus aureus in the United States, 2002-2006. Clin Infect Dis 2008;46:668674.Google Scholar
9.Cannelli, Y, Eliopoulis, G, Mozaffari, E, Samore, M. Health and economie outcomes of vancomycin-resistant enterococci. Arch Intern Med 2002;162:22232228.Google Scholar
10.Ofher-Agostini, M, Johnston, BL, Simor, AE, et al.Vancomycin-resistant enterococci in Canada: results from the Canadian Nosocomial Infection Surveillance Program, 1999-2005. Infect Control Hosp Epidemiol 2008;29:271274.Google Scholar